Understand a newer treatment approach for pulmonary hypertension that targets the activin signaling pathway. Christopher King explains how imbalances in substances such as bone morphogenic protein and activin can lead to higher lung pressures and cause blood vessel tightening and how activin signaling medications may help restore balance, improve blood flow, and support healthier blood vessels. You will also learn what to expect with treatment, including how it’s given, lab monitoring, possible side effects, and the importance of working with your health care team to create a treatment plan that fits your needs.

Speaker

Christopher King, MD, FCCP
Associate Medical Director, Advanced Lung Disease and Transplant Program
PFF Center Director
Associate Medical Director, PAH and CTEPH Program
System Director, Respiratory Care Services